High Cardiac Risk With Sutent

As Reported by HealthDay News. 2008 Feb 13

Sutent (sunitinib), a drug for kidney cancer and gastrointestinal stromal tumors, has a significant risk for cardiac side effects. New research has found that the risk is higher than previously believed. The new data, which will be presented at the ASCO...

NOT A MEMBER?

OncologySTAT registration is FREE and takes less than a minute to complete. Registration provides instant access to 100+ Elsevier cancer-related journals, journal scans, daily medical and regulatory news, professional drug and interactions databases, chemotherapy regimens, and InfoBLAST - OncologySTAT's weekly e-newsletter.

 
Comment Print page RSS feeds

Follow OncologySTAT on Twitter

Look for news reports from ASCO and other major conferences, journal scans, and more.
Start following ›

Sign up for our newsletters

Too busy to follow cancer's top stories? Sign-up for 1 or more of our newsletters -- delivered weekly to your inbox.
Register today to receive free e-newsletters ›

Cancer Types Spotlight

more types
close
  • Bladder
  • Bone
  • Breast
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • HIV-Related Cancers
  • Hodgkin's Lymphoma
  • Bladder
  • Bone
  • Breast
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • HIV-Related Cancers
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin (Melanoma)
  • Skin (Non-Melanoma)
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
    • Forgot your password?
    Not a member? Free registration